A comprehensive analysis of cancer statistics found that incidence rates of 14 cancer types increased among people under age 50. Researchers speculate that risk factors such as obesity and changes in cancer screening may contribute to these increases.
A new form of tumor infiltrating lymphocyte (TIL) therapy improved treatment's effectiveness in patients with metastatic gastrointestinal cancers. Objective responses were seen in multiple types of gastrointestinal cancers, including colon, rectum, pancreas, and bile duct tumors.
A new NIH study found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than those who were more sedentary. The researchers also discovered that higher daily step count was associated with a reduced risk of cancer, regardless of the pace of steps.
A recent NIH study found that prevention and screening interventions saved an estimated 4.75 million lives between 1975 and 2020, surpassing the impact of treatment advances for five major cancer types: breast, cervical, colorectal, lung, and prostate cancers.
Researchers discovered a new role of mutant RAS genes in driving tumor growth beyond their well-known signaling function. Combining RAS inhibitors with targeted cancer drugs that reactivate tumor suppressor activity had potent activity against cancer.
A new NIH study finds that West African genetic ancestry is linked to increased prostate cancer risk among men living in disadvantaged neighborhoods, possibly due to chronic stress. The study suggests that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.
A new clinical trial shows that immunotherapy treatment with pembrolizumab can significantly extend the cancer-free period for patients with high-risk, muscle-invasive bladder cancer. The study found that adjuvant pembrolizumab treatment nearly doubled the median length of time patients remained cancer-free compared to observation.
A new cellular immunotherapy approach shrank tumors in several patients with metastatic colon cancer, showing promise for treating other solid cancers. The treatment involved genetically engineered lymphocytes that recognized and attacked specific cancer cells.
A large analysis of data from nearly 400,000 healthy U.S. adults found no association between regular multivitamin use and lower risk of death or cardiovascular disease, cancer mortality. The study's results provide new insights into the relationship between multivitamin use and health outcomes in this population.
Researchers at NIH developed a non-chemotherapy treatment regimen that achieved full remissions for some patients with relapsed or refractory DLBCL. The five-drug combination targeted multiple molecular pathways, resulting in substantial tumor shrinkage and complete responses in 38% of evaluable patients.
Researchers identified genetic variants associated with mosaic loss of chromosome X (mLOX), which can lead to cancer and blood disorders. Inherited genetic variants near genes for autoimmune diseases and cancer susceptibility were found to influence mLOX development.
The report found that new diagnoses of six major cancer types declined sharply in early 2020, coinciding with the start of the COVID-19 pandemic. Cancer screenings and other procedures were also significantly reduced, likely due to medical care interruptions.
The Biden-Harris Administration has launched a $50 million initiative to improve cancer outcomes in persistent poverty areas. The Persistent Poverty Initiative aims to build research capacity, foster cancer prevention research, and promote community-based programs to address the cumulative effects of poverty on cancer outcomes.
Researchers at the National Institutes of Health have found that immunotherapy can prevent the progression of low-grade lymphomatoid granulomatosis to high-grade disease. The treatment significantly improves survival rates for patients with the rare precancerous condition, with a median overall survival of over 20 years.
The National Cancer Institute has approved atezolizumab, an immunotherapy drug, for the treatment of adults and children with advanced alveolar soft part sarcoma. The approval is based on a phase 2 trial that showed significant tumor shrinkage in about a third of patients.
The annual report shows a continued decline in overall cancer death rates among men, women, children, and adolescents. Additionally, there are modest improvements in survival for pancreatic cancer, with declines seen in lung cancer and melanoma.
A recent study found that former smokers who stick to a healthy lifestyle have a lower risk of dying from all causes, including cancer and heart and lung diseases. The study analyzed data from over 159,000 former smokers and found that maintaining a healthy lifestyle was associated with a 27% reduction in the risk of death.
Older adults who engage in weekly leisure time activities such as walking, jogging, or playing tennis may have a lower risk of death from any cause, cardiovascular disease, and cancer. Achieving recommended physical activity levels through various activities can lead to significant reductions in mortality risk.
A large clinical trial found that treating high-grade squamous intraepithelial lesions (HSIL) reduces the risk of anal cancer in people with HIV. The study showed a 57% reduction in anal cancer cases after treatment, highlighting the importance of screening and treatment for HSIL in this population.
Cancer death rates among Black people decreased steadily between 1999 and 2019, yet they remained significantly higher compared to other racial and ethnic groups. The study highlights the need for improved access to cancer screening, earlier detection, and quality care, as systemic barriers contribute to disparities in cancer outcomes.
The NCI has launched a program to provide molecular characterization of childhood cancers, allowing for accurate diagnoses and personalized treatment. The program will expand to include soft tissue sarcomas and other rare tumors, and data collected will be shared among researchers to accelerate the development of new treatments.
Researchers used a patient's own immune cells to target unique mutations in tumor DNA, leading to measurable tumor shrinkage in 67% of patients with metastatic breast cancer. The approach has potential as a personalized treatment for hormone receptor-positive breast cancers.
A high-fiber diet has been shown to improve the response of melanoma patients to immunotherapy by influencing the gut microbiome. Patients who consumed at least 20 grams of dietary fiber per day lived longer without their cancer progressing, compared to those who consumed less fiber.
A clinical trial found that a drug combination of all-trans retinoic acid and arsenic trioxide is highly effective in treating standard- and high-risk acute promyelocytic leukemia in children, with nearly all patients surviving for two years without relapse. The treatment reduces the need for conventional chemotherapy, offering fewer s...
Adding ibrutinib to standard chemotherapy regimens can improve survival in younger patients with specific genetic subtypes of non-GCB DLBCL, with MCD and N1 subtypes showing exceptional response rates. However, older patients did not benefit from the treatment combination.
A new report reveals that cancer patients in the US bear a significant financial burden, with total out-of-pocket costs reaching over $21 billion in 2019. The majority of these costs are associated with breast and prostate cancers, which are among the most prevalent types in the country.
A recent NCI study highlights the significant disparities in COVID-19 mortality among racial and ethnic groups in the US. Excess deaths by population size among Black, American Indian/Alaska Native, and Latino individuals were more than double those in white and Asian individuals.
A genomic analysis of lung cancer in people with no smoking history identified three molecular subtypes, including the slow-growing 'piano' subtype and the aggressive 'forte' subtype. The study aims to guide clinical treatments based on these subtypes, which may have different prevention and treatment approaches.
Researchers developed a blood test to detect cancer early in people with NF1, a genetic disorder that affects 1 in 3,000 people worldwide. The test differentiates between benign and aggressive tumors with high accuracy and could help monitor treatment responses.
An international study on rare childhood cancer, rhabdomyosarcoma, found that mutations in genes TP53, MYOD1, and CDKN2A are associated with a more aggressive form of the disease. The study provides genetic clues for developing targeted therapies.
Researchers used genomic tools to investigate health effects of Chernobyl radiation, finding no evidence of genetic changes passed from parents to children. The studies identified genetic changes in thyroid cancer tumors of people exposed as children or fetuses to radiation released by the accident.
Scientists genetically engineered myeloid cells to deliver an anticancer signal, shrinking tumors and preventing cancer from spreading to other parts of the body. The study shows promise as a potential treatment for metastatic cancer, with treated mice living substantially longer and experiencing reduced metastatic cancer.
A recent NCI study found that individuals with SARS-CoV-2 antibodies appear well protected against re-infection for several months. The study analyzed data from over 3 million people and showed a significant decrease in positive NAAT test results among those with antibodies.
A new study suggests that fecal microbiota transplants can help patients with advanced melanoma respond to immunotherapy drugs. After receiving a transplant, six out of 15 patients showed improved cancer stability or tumor reduction.
A study of patients with cancer who had exceptional responses to therapy has identified molecular changes in their tumors that contribute to these unexpected and long-lasting responses. The researchers used genomic characterizations to uncover genetic alterations that may help understand the mechanisms behind these rare responses.
The National Cancer Institute (NCI) and Cancer Research UK will establish the Cancer Grand Challenges program to tackle cancer research challenges. The initiative aims to facilitate global collaboration, foster innovation, and accelerate progress against cancer.
Recent advances in treatment have led to a sharp reduction in lung cancer mortality rates in the US, with non-small cell lung cancer deaths decreasing faster than incidence. The study found significant improvements in survival for both men and women, particularly after the introduction of targeted therapies.
Researchers developed a blood test that detects viral exposure signatures linked to liver cancer risk. The test showed high accuracy in distinguishing patients with hepatocellular carcinoma from those with chronic liver disease and healthy volunteers. It has the potential to improve liver cancer screening and early detection.
Researchers found that blocking Bruton tyrosine kinase (BTK) protein with acalabrutinib reduced inflammation and improved breathing in patients with severe COVID-19. The study suggests a potential new treatment approach for hospitalized patients with low blood-oxygen levels and evidence of inflammation.
The dose-adjusted (DA) EPOCH-R regimen was found to be highly effective and better tolerated than standard chemotherapy for adults with Burkitt lymphoma. The treatment was effective across age groups, including patients in their 70s and 80s, and regardless of HIV status.
A new study found that taking higher daily step counts is associated with a lower risk of death from all causes. The study tracked over 4,800 U.S. adults and found that those who took 8,000 steps per day had a 51% lower risk compared to those who took 4,000 steps.
A recent NIH study has found that a significant proportion of children with osteosarcoma carry genetic variants associated with increased cancer risk. The researchers identified harmful or likely harmful variants in over a quarter of patients, highlighting the importance of genetic testing and screening for family members.
A phase 2 clinical trial conducted by the National Cancer Institute found that selumetinib improved outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors and reducing pain. The treatment also led to clinically meaningful improvements in quality of life, strength, and range of motion.
Researchers found that using AI to analyze CT scans can produce more accurate risk assessment for major cardiovascular events. Automated CT-based body composition biomarkers outperformed established clinical parameters like Framingham risk score and BMI in predicting adverse events.
A new testing method combining systematic biopsy with MRI-targeted biopsy leads to more accurate diagnoses and better treatment outcomes for prostate cancer patients. The study found that combined biopsy provided more accurate diagnoses than MRI-targeted biopsies alone, reducing the risk of overtreatment and undertreatment.
Blinatumomab treatment demonstrates longer survival, fewer severe side effects, and higher undetectable residual disease rates compared to standard chemotherapy for children with high- or intermediate-risk B-cell acute lymphoblastic leukemia. The study shows promising results as a bridge to curative bone marrow transplant.
A recent study by the SWOG Cancer Research Network found that nearly half of phase 3 cancer clinical trials sponsored by the National Cancer Institute (NCI) were associated with new cancer care guidelines or new drug approvals. The analysis suggests that NCTN trials contribute to cost-effective evidence guiding cancer patient care.
A study by the National Cancer Institute found a clear dose-response relationship between radioactive iodine treatment and long-term risk of death from solid cancers, including breast cancer. The study estimated that for every 1,000 patients treated with standard doses, about 20-30 additional solid cancer deaths would occur.
The latest Annual Report to the Nation on Cancer finds that overall cancer death rates continue to decline in the US. However, a special section reveals a different picture for adults ages 20-49, with higher incidence and mortality among women than men.
Incidence rates of uterine cancer's aggressive subtypes increased dramatically among all racial groups from 2000 to 2015, with black women having higher rates and poorer survival. Endometrioid subtypes showed stable trends in white women but increasing rates in other groups.